Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals (Q46118142)

19 December 2017

title

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals (English)

1 reference

19 December 2017

1 reference

1 reference

9

1 reference

19 December 2017

Chantal Csajka

12

1 reference

19 December 2017

Swiss HIV Cohort Study

13

object named as

Swiss HIV Cohort Study

1 reference

19 December 2017

T Buclin

3

0 references

Matthias Cavassini

0 references

author name string

M Arab-Alameddine

1

1 reference

19 December 2017

J Di Iulio

2

1 reference

19 December 2017

M Rotger

4

1 reference

19 December 2017

R Lubomirov

5

1 reference

19 December 2017

M Cavassini

6

1 reference

19 December 2017

A Fayet

7

1 reference

19 December 2017

L A Décosterd

8

1 reference

19 December 2017

J Biollaz

10

1 reference

19 December 2017

A Telenti

11

1 reference

19 December 2017

language of work or name

English

0 references

publication date

18 February 2009

1 reference

19 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

19 December 2017

volume

85

1 reference

19 December 2017

issue

5

1 reference

19 December 2017

page(s)

485-494

1 reference

19 December 2017

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Antiretroviral pharmacokinetic profile: a review of sex differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

Population pharmacokinetic meta-analysis with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

inferred from DOI database lookup

7 January 2021

based on heuristic

Common allelic variants of cytochrome P4503A4 and their prevalence in different populations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.271

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2008.271

1 reference

19 December 2017

1 reference

19 December 2017